Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target

Yasir J Sepah; Gabriel Velez; Peter H Tang; Jing Yang; Teja Chemudupati; Angela S Li; Quan D Nguyen; Alexander G Bassuk; Vinit B Mahajan

doi:10.1016/j.ajoc.2020.100646

Back

Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target

Journal article

Open access

Peer reviewed

Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target

Yasir J Sepah, Gabriel Velez, Peter H Tang, Jing Yang, Teja Chemudupati, Angela S Li, Quan D Nguyen, Alexander G Bassuk and Vinit B Mahajan

American journal of ophthalmology case reports, Vol.18, p.100646

06/2020

DOI: 10.1016/j.ajoc.2020.100646

PMCID: PMC7132169

PMID: 32274442

Files and links (1)

url

https://doi.org/10.1016/j.ajoc.2020.100646View

Published (Version of record) Open Access

Abstract

To profile vitreous protein expression of intermediate uveitis (IU) patients. We identified a mean of 363 ± 41 unique proteins (mean ± SD) in IU vitreous and 393 ± 69 unique proteins in control samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of liquid vitreous biopsies collected during pars plana vitrectomy. A total of 233 proteins were differentially expressed among control and IU samples, suggesting a protein signature that could distinguish the two groups. Pathway analysis identified 22 inflammatory mediators of the interleukin-12 (IL-12) signaling pathway in IU vitreous. Upstream regulator analysis identified downstream mediators of IL-23 and myeloid differentiation primary response protein (MYD88), both of which are involved in the recruitment and differentiation of myeloid cells. Taken together, our results suggest the recruitment of myeloid cells as an upstream pathway in the pathogenesis of IU. This study provides insights into proteins that will serve as biomarkers and therapeutic targets for IU. These biomarkers will help design future clinical trials using rational molecular therapeutics.

Intermediate uveitis

Vitreous

Biomarker

Proteomics

Details

Title: Subtitle: Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target
Creators: Yasir J Sepah - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Gabriel Velez - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Peter H Tang - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Jing Yang - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Teja Chemudupati - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Angela S Li - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Quan D Nguyen - Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA, USA
Alexander G Bassuk - Department of Pediatrics, University of Iowa, Iowa City, IA, USA
Vinit B Mahajan - Omics Laboratory, Stanford University, Palo Alto, CA, USA
Resource Type: Journal article
Publication Details: American journal of ophthalmology case reports, Vol.18, p.100646
DOI: 10.1016/j.ajoc.2020.100646
PMID: 32274442
PMCID: PMC7132169
NLM abbreviation: Am J Ophthalmol Case Rep
ISSN: 2451-9936
eISSN: 2451-9936
Publisher: Elsevier Inc
Grant note: DOI: 10.13039/100000002, name: NIH, award: K08EY020530, R01EY024665, R01EY025225, R01EY024698, R21AG050437, P30EY026877; DOI: 10.13039/100000862, name: Doris Duke Charitable Foundation, award: #2013103; DOI: 10.13039/100001818, name: Research to Prevent Blindness; DOI: 10.13039/100000002, name: NIH, award: F30EYE027986, T32GM007337
Language: English
Date published: 06/2020
Academic Unit: Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
Record Identifier: 9984070961902771

Metrics

15 Record Views